| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -69,680 | -82,440 | -91,170 | -125,600 | -67,250 |
| Net Income Growth | +15.48% | +9.58% | +27.41% | -86.77% | -90.73% |
Black Diamond Therapeutics Inc (BDTX)
1.5600 x 27 1.6000 x 6
Pre-market by (Cboe BZX)
1.5500 -0.0600 (-3.73%) 03/31/25 [NASDAQ]
1.5600 x 27 1.6000 x 6
Pre-market 1.5600 +0.0100 (+0.65%) 08:02 ET
for Mon, Mar 31st, 2025
Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts.
Fiscal Year End Date: 12/31